Pentraxin 3 as a marker of endothelial dysfunction in young women with polycystic ovary syndrome (PCOS)

References

• Galluzzo A, Amato MC, Giordano C. Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis. 2008;18:511–518.
   PubMed Web of Science ®Google Scholar
• Cho LW, Randeva HS, Atkin SL. Cardiometabolic aspects of polycystic ovarian syndrome. Vasc Health Risk Manag. 2007;3:55–63.
   PubMedGoogle Scholar
• Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002;77:1095–1105.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest. 2006;36:691–697.
   PubMed Web of Science ®Google Scholar
• Aydogdu A, Tasci I, Tapan S, et al. High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2012;28:722–725.
   PubMed Web of Science ®Google Scholar
• Deveer M, Deveer R, Basaran O, et al. Serum copeptin, pentraxin 3, anti-Mullerian hormone levels with echocardiography and carotid artery intima-media thickness in adolescents with polycystic ovary syndrome. J Clin Med Res. 2015;7:989–994.
   PubMedGoogle Scholar
• Fornai F, Carrizzo A, Forte M, et al. The inflammatory protein Pentraxin 3 in cardiovascular disease. Immun Ageing. 2016;13:25.
   PubMed Web of Science ®Google Scholar
• Liu S, Qu X, Liu F, et al. Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection. Mediators Inflamm. 2014;2014:421429.
   PubMed Web of Science ®Google Scholar
• Kunes P, Holubcova Z, Kolackova M, et al. Pentraxin 3. (PTX 3): an endogenous modulator of the inflammatory response. Mediators Inflamm. 2012;2012:1.
   Web of Science ®Google Scholar
• Introna M, Alles VV, Castellano M, et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood. 1996;87:1862–1872.
   PubMed Web of Science ®Google Scholar
• Bottazzi B, Doni A, Garlanda C, et al. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010;28:157–183.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Jeannin P, Hamon Y, et al. Endogenous PTX3 translocates at the membrane of late apoptotic human neutrophils and is involved in their engulfment by macrophages. Cell Death Differ. 2009;16:465–474.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Valentino S, Gentile S, et al. The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules. Ann NY Acad Sci. 2013;1285:1–14.
   PubMed Web of Science ®Google Scholar
• Garlanda C, Hirsch E, Bozza S, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002;420:182–186.
   PubMed Web of Science ®Google Scholar
• Daigo K, Inforzato A, Barajon I, et al. Pentraxins in the activation and regulation of innate immunity. Immunol Rev. 2016;274:202–217.
   PubMed Web of Science ®Google Scholar
• Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem. 1997;272:32817–32823.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Bottazzi B, Mantovani A, et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol. 2003;33:465–473.
   PubMed Web of Science ®Google Scholar
• Ma YJ, Doni A, Romani L, et al. Ficolin-1-PTX3 complex formation promotes clearance of altered self-cells and modulates IL-8 production. J Immunol. 2013;191:1324–1333.
   PubMed Web of Science ®Google Scholar
• Ma YJ, Doni A, Hummelshøj T, et al. Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition. J Biol Chem. 2009;284:28263–28275.
   PubMed Web of Science ®Google Scholar
• Ma YJ, Doni A, Skjoedt MO, et al. Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system. J Biol Chem. 2011;286:3405–3417.
   PubMed Web of Science ®Google Scholar
• Deban L, Jarva H, Lehtinen MJ, et al. Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J Immunol. 2008;181:8433–8440.
   PubMed Web of Science ®Google Scholar
• Moalli F, Doni A, Deban L, et al. Role of complement and Fcgamma receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus. Blood. 2010;1161:5170–5180.
   Google Scholar
• Rusnati M, Camozzi M, Moroni E, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood. 2004;104:92–99.
   PubMed Web of Science ®Google Scholar
• Doni A, Musso T, Morone D, et al. An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. J Exp Med. 2015;212:905–925.
   PubMed Web of Science ®Google Scholar
• Camaioni A, Klinger FG, Campagnolo L, et al. The influence of Pentraxin 3 on the ovarian function and its impact on fertility. Front Immunol. 2018;9:2808.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. ATVB. 2007;27:161–167.
   Google Scholar
• Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636–641.
   PubMed Web of Science ®Google Scholar
• Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110:2349–2354.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Takeishi Y, Niizeki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008;155:75–81.
   PubMed Web of Science ®Google Scholar
• Jenny NS, Arnold AM, Kuller LH, et al. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the cardiovascular health study. ATVB. 2009;29:594–599.
   Google Scholar
• Dubin R, Li Y, Ix JH, et al. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J. 2012;163:274–279.
   PubMed Web of Science ®Google Scholar
• Nerkiz P, Doganer YC, Aydogan U, et al. Serum pentraxin-3 level in patients who underwent coronary angiography and relationship with coronary atherosclerosis. Med Princ Pract. 2015;24:369–375.
   PubMed Web of Science ®Google Scholar
• Shindo A, Tanemura H, Yata K, et al. Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability. PLoS One. 2014;9:e100045.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
   Web of Science ®Google Scholar
• Obesity: Preventing and managing the global epidemic. Report of a WHO, Geneva; 1998.
   Google Scholar
• Yasunaga T, Ikeda S, Koga S, et al. Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein. Int Heart J. 2014;55:160–164.
   PubMed Web of Science ®Google Scholar
• Alp Ç, Dogru MT, Karadeniz M, et al. Serum pentraxin-3 levels and flow-mediated dilation in dipper and non-dipper hypertension. J Clin Lab Anal. 2019;33:e22718.
   PubMed Web of Science ®Google Scholar